Kimia Therapeutics
CA - BerkeleyBiotechnology
Focus: Kimia Therapeutics is a Berkeley-based biotech focused on metabolic disease treatment with a diversified pipeline spanning dermatology, infectious disease, and vaccine development. The company operates at pre-revenue stage with early-to-mid stage clinical programs.
Profile data last refreshed 15h ago · AI intelligence enriched 1w ago
Open Jobs
0
About Kimia Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Kimia Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
3/9 — Basic
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Acyclovir 200 MG
Drug UseClinical Trials (1)
NCT04988646Pharmacokinetic Properties of 200 and 400 mg Acyclovir Tablet in Indonesia Healthy Subject
N/AHelp build intelligence for Kimia Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.